A Potentially Important Treatment After Blast-Induced Brain Injury!! NAC The study should be shared with the medical and research authorities of the IDF,

Allthatcanheal: Our army!!! Tzahal NAC: A Potentially Important Treatment After Blast-Induced Brain Injury
N-acetylcysteine (NAC) is an inexpensive and widely available compound that deserves attention because of its potential role in treating mild traumatic brain injury (mTBI) caused by blast exposure.
A double-blind, placebo-controlled study involving 81 U.S. military personnel in Iraq examined the effects of NAC following blast exposure.
Key Findings
Treatment with NAC was associated with significantly greater resolution of symptoms within seven days.
Among participants who received treatment within 24 hours of the blast, 86% of patients treated with NAC experienced complete symptom resolution, compared with 42% in the placebo group.
Symptoms evaluated in the study included headaches, dizziness, hearing loss, memory problems, sleep disturbances, and cognitive difficulties.
Why Is This Important for the Israel Defense Forces (IDF)?
These findings justify further consideration and investigation of whether NAC could help Israeli soldiers exposed to blast-related injuries. Rapid medical assessment and early treatment after a blast event may be particularly important.
Study source: Hoffer ME et al. Amelioration of acute sequelae of blast induced mild traumatic brain injury by N-acetyl cysteine: a double-blind, placebo controlled study.
Important: This was a relatively small study that evaluated only short-term outcomes. Additional research is needed to determine how consistently effective NAC is, to establish the optimal treatment protocol, and to clarify its potential long-term benefits. NAC should not be used as a substitute for standard medical evaluation and treatment following blast injury.
My Comments on the Scientific Evidence
In my view, this study is important enough to be brought to the attention of the medical authorities within the IDF. The fact that it was conducted under combat conditions makes it particularly relevant. However, the study was published in 2013, and its findings still require confirmation in larger studies.
NAC and Parkinson’s Disease
There are also preliminary studies suggesting a possible benefit of NAC in Parkinson’s disease, including a small pilot placebo-controlled study published in 2026.
The evidence is still not strong enough to recommend NAC as a routine treatment for Parkinson’s disease. Anyone considering its use should consult their treating neurologist and should not replace prescribed therapy with NAC.
My Main Recommendation
The study should be shared with the medical and research authorities of the IDF, and it would be worthwhile to determine whether NAC has been evaluated as an option for the early treatment of mild traumatic brain injury caused by blast exposure.
This is a legitimate medical and research question, but NAC should not yet be regarded as a proven treatment protocol.
For the full original study, see PubMed Central.
[10/28/2026 12:00 PM]